NVCR - NovoCure Limited
95.20 +0.41 (0.43%)
After hours: 7:05PM EST
| Previous Close | 95.65 |
| Open | 96.12 |
| Bid | 94.10 x 1000 |
| Ask | 94.84 x 1000 |
| Day's Range | 94.63 - 98.75 |
| 52 Week Range | 41.51 - 98.75 |
| Volume | 836,208 |
| Avg. Volume | 897,569 |
| Market Cap | 9.381B |
| Beta (5Y Monthly) | 2.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.29 |
| Earnings Date | Feb 26, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 90.43 |
- Investor's Business Daily
Why This Leading Medtech Stock Nabbed A Second Breakout In A Week
Novocure stock broke out of a cup-with-handle base Tuesday after the company's cancer treatment device, dubbed Optune, gained insurance coverage in Israel for newly diagnosed glioblastoma.
- Business Wire
Novocure Announces National Reimbursement in Israel for Optune® in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Novocure announced national reimbursement in Israel for Optune® in combination with temozolomide for the treatment of newly diagnosed glioblastoma.
- Investor's Business Daily
Stock Market Sets More Record Highs; Home Depot, Pinterest, Tesla, Twitter Key Movers
The major stock indexes were squarely higher Friday morning, as they set more record highs. Dow Jones stock Home Depot offers a new buy point.
- Investor's Business Daily
IBD Stock Of The Day Breaks Out On Bullish Preliminary Sales Report
Novocure is the IBD Stock Of The Day as shares of the cancer treatment specialist break out of a double-bottom chart pattern following a strong preliminary fourth-quarter sales report.
- Business Wire
Novocure Announces Fourth Quarter and Full Year 2019 Preliminary Net Revenues and Provides Company Update
Novocure reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2019.
- GlobeNewswire
Zai Lab and Novocure Announce First Patient Enrolled in a Phase 2 Pilot Trial of Tumor Treating Fields Together with Chemotherapy as First-Line Treatment of Gastric Cancer
Zai Lab Limited (ZLAB), a China and U.S.-based innovative commercial stage biopharmaceutical company, and Novocure (NVCR), a global oncology company with a proprietary platform technology called Tumor Treating Fields, today announced that the first patient has been enrolled in a phase 2 pilot clinical trial evaluating the safety and efficacy of Tumor Treating Fields in combination with chemotherapy as a first-line treatment in patients with gastric adenocarcinoma. “Zai Lab licensed Tumor Treating Fields from Novocure in September 2018, and we have since launched Optune® in Hong Kong for the treatment of patients with recurrent, or newly diagnosed glioblastoma multiforme (GBM) and submitted a Marketing Authorization Application to the China National Medical Products Administration (NMPA) for approval,” said Dr. Samantha Du, Founder and CEO of Zai Lab.
- Business Wire
Novocure to Participate in the 38th Annual J.P. Morgan Healthcare Conference
Novocure will participate in the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020, in San Francisco.
- Insider Monkey
Here’s What Hedge Funds Think About NovoCure Limited (NVCR)
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
- GlobeNewswire
SI-BONE Names Jeryl (“Jeri”) Hilleman to Board of Directors
SANTA CLARA, Calif., Dec. 04, 2019 -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the.
- TheStreet.com
Raise Stops on NovoCure
NovoCure Ltd. was favored by Jim Cramer during the Lightning Round segment of " Mad Money" Tuesday night. In this daily bar chart of NVCR, below, we can see that prices took about two months to decline in September and October, but retraced nearly that entire decline in just one month. This movement is not an indicator, but I consider this observation a sign of strength in that prices have gone up faster than they went down.
- Business Wire
Novocure and the AACR Announce 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research Program
Novocure (NVCR) and the American Association for Cancer Research (AACR) announce today their 2nd Annual AACR-Novocure Grants for Tumor Treating Fields Research program. The program represents a joint effort to promote and support innovative research on Tumor Treating Fields to help deepen the understanding of the mechanism of action and to accelerate the development of new treatment strategies. The program includes research grants and career development awards totaling more than $2 million over the next three years.
- MoneyShow
Novocure- A New Way to Target Tumors
Medical stocks look like the early leaders of this market advance, and Novocure (NVCR) is one that had a nice run earlier this year and is now shaping up a great-looking launching pad, explains growth stock expert Mike Cintolo, editor of Cabot Top Ten Trader.
- TEST Business Wire Releases
Novocure to Participate in the Evercore ISI 2019 HealthCONx Conference
Novocure Executive Chairman William Doyle will participate in the Evercore ISI 2019 HealthCONx Conference on December 5, 2019, in Boston.
- Business Wire
Novocure Announces 43 Presentations on Tumor Treating Fields at 24th Annual Meeting of the Society for Neuro-Oncology
Presentations on Tumor Treating Fields cover a broad and growing range of topics, with nearly 80 percent of presentations prepared by external authors
- Thomson Reuters StreetEvents
Edited Transcript of NVCR earnings conference call or presentation 31-Oct-19 12:00pm GMT
Q3 2019 Novocure Ltd Earnings Call
- TheStreet.com
NovoCure Looks Ready to Resume Its Strong Uptrend After a Correction
The downside correction in NovoCure looks like it has run its course. NVCR is looking ready to resume its uptrend. In this daily bar chart of NVCR, below, it looks like prices are bottoming again after a declining phase from late August.
- Zacks
NovoCure (NVCR) Q3 Earnings and Revenues Beat Estimates
NovoCure (NVCR) delivered earnings and revenue surprises of 140.00% and 4.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- ACCESSWIRE
Novocure Ltd. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / October 31, 2019 / Novocure Ltd. (NASDAQ: NVCR ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on October 31, 2019 at 8:00 AM Eastern ...
- Business Wire
Novocure Reports Third Quarter 2019 Financial Results and Provides Company Update
Quarterly net revenues of $92.1 million, representing 42% growth versus the third quarter 2018
- TipRanks
3 Monster Growth Stocks to Hold Through 2020
The name of the game is growth; that’s what investors are looking for. Growth ensures profits, profits boost share prices, and higher share prices are the investor’s goal. In truth, this should not come as a surprise; the S&P 500 is up over 20% year-to-date, and statistically speaking, that sort of gain must encompass some stocks that are growing far faster.We’ve opened up TipRanks’ Best Stocks to Buy to find three buy-rated stocks that have more than doubled so far in 2019. But more importantly, analysts believe there's more upside in store heading into 2020; all three of these stocks show more than 30% upside potential. The stocks cover a wide range of market sectors – social media, online games, and biotechnology – reflecting the market reality that great opportunities abound, for investors willing to look.Sea Limited (SE)The online gaming sector has the benefit of devoted fans who will eagerly snap up their favorite companies’ latest offerings – but it has the risk of a tech-savvy fan base that won’t be amused by substandard offerings. Sea Limited owns and maintains a number of active titles in the Battle Royale genre, including Free Fire and Ring of Elysium. The company’s PUBG Lite was the most popular Battle Royale mobile game in South East Asia in the third quarter of this year, followed by SE’s Garena Free Fire. SE games rank among the top 10 grossing ranks in 51 as of this past September.Popular games are the path to profits, and SE announced a 203% year-over-year revenue gain in Q2 2019, reporting $665.4 million compared to $219.6 million in the prior-year quarter. Quarterly active users (QAU) gained 93% year-over-year, reaching 310.5 million. Of that total, 8.4% were quarterly paying users – more than double the year-ago number. With pre-registration starting for Call of Duty: Mobile, a collaboration with online giants Activision Tencent, Sea has excellent prospects to keep increasing its active and paying user numbers. The strongly positive outlook has pushed this stock up 151% year-to-date.Credit Suisse analyst Varun Ahuja was duly impressed. He reiterated his Outperform rating (an equivalent to Buy), while slightly increasing the price target from $43 to $44. His price target suggests a robust 54% upside potential. (To watch Ahuja's track record, click here)Ahuja wrote, “For 3Q19, we are building in gaming revenue to grow by c.4% QoQ as the growth in Free Fire is likely to be offset by slowdown in other mobile games… SEA Ltd's stock price has corrected by c.15% post the 2Q19 results. We see the correction as a strong accumulating opportunity given that its underlying fundamentals remain solid.”JPMorgan's team added, “SE’s share price declined by 9% on 8 October (CCMP -1.7%). Different investors attributed the sell-off to different reasons. Interestingly though, none of the factors created a major concern on their own but together resulted in a sell-off in a weak market. We remain OW on SE and see improving monthly gaming revenues…” The firm gives this stock a $41 price target, indicative of a 43% upside.So, the consensus on SE is ‘buy the dip.’ The stock has a Strong Buy consensus rating, based on 5 positive reviews in the last three months. Shares or selling for $28.50, and the $44 average price target suggests an upside potential of 54%. (Sea Limited stock analysis on TipRanks)Snap, Inc. (SNAP)With Snap, we get into social media. The popular Snapchat app allows users to put a variety of funny filters on their smartphone photos, use image messaging, chat and exchange images with other users, and create and share ephemeral online ‘stories.’ The company’s other products include Spectacles, a wearable camera, and Bitmoji, a personalized sticker spin-off of the popular Bitstrip cartoon app.Snap went public in 2017 and has been volatile ever since. The market downturn in 2H 2018 hit the company hard, and shares lost 64%. SNAP has recovered since and is now trading 179% higher than its December 2018 bottom. For the year-to-date, SNAP is up 153%.In its most recent earnings report, for Q3, SNAP reported a series of strong metrics. Daily active users were up to 210 million, revenues were up to $446 million, and the reported loss per share was 4 cents. The forecasts had called for 207 million DAUs, revenues of $435.1 million, and a 5 cent EPS loss. The gains were welcome news, because the company lowered guidance for forward revenues, to the $540 to $560 million range, while the expectation had been for $555. Shares slipped on the lower guidance.Top analysts see SNAP’s recent share price slip as a buying opportunity. Writing from JPMorgan, 5-star analyst Doug Anmuth said, “We believe Snap shares are increasingly compelling following a 20%+ pullback from recent highs and after delivering 3Q results that we believe showed more encouraging trends. Importantly, we believe that Snap's platform and business have both improved dramatically over the past several quarters…” Anmuth’s $20 price target implies an upside potential of 43%. (To watch Anmuth's track record, click here)Ross Sandler, from Barclays, also gives SNAP a Buy rating, explaining his stance with several points: “We are Overweight based on 5 key elements: 1) SNAP’s Ad revenue headwind is almost done, 2) the overall narrative may change in 2019, 3) new Ad formats could help starting 1Q19, 4) short interest is high, and 5) SNAP could see stronger user growth in early 2019.”SNAP’s analyst consensus rating is a Moderate Buy, based on 11 Buys and 10 Holds set in the past three months. The average price target of $18.82 suggests a healthy upside potential of 34% from the current trading price of $13.96. (See Snap stock analysis on TipRanks)NovoCure (NVCR)The biotech industry is known for its high upside potential, and also its risk. This is not a field for fainthearted investors – it is capital intensive, and slow to show returns. A failed drug trial or a denial of regulatory approval can spell ruin. But once a new product shows its worth, the profits can be staggering. So, it should come as no surprise that NovoCure stock shows a 43% upside potential.The company inhabits the cancer treatment niche. The company’s product, Optune, is not a drug; rather, it uses specially tuned electrical fields (Tumor Treating Fields) to disrupt the growth and division of cancer cells in tumors. Optune was designed to combat recurrent glioblastoma, and received FDA approval in 2015. The company currently markets the treatment system actively in the United States, Europe (Germany, Austria, Switzerland, and Sweden), Israel, and Japan.NovoCure’s pipeline includes trials of Optune as a treatment for six other cancers: non-small cell lung cancer (NSCLC), liver cancer, pancreatic cancer, ovarian cancer, liver cancer, and mesothelioma. These trials of Tumor Treating Fields have reached Phase 3 as of this year.A unique product, with FDA approval, and the prospect of applications beyond its original target are all positive aspects for a biotech company, and NovoCure’s earnings and revenues have reflected this. Like many small to medium biotech startups, the company is still in the red, but earnings are on an upward trajectory and have beaten the forecasts twice in the last four quarters. In the most recent report, for Q2 2019, NVCR showed a loss of 1 cent per share, well ahead of the forecast 7 cent loss and far better than the year-ago loss of 17 cents. Revenues came in at $86.7 million, beating the estimates by 6.4%. Despite a slip in recent weeks, NVCR stock is up 104% so far this year.This company’s strong performance has attracted a laudatory review from Oppenheimer. Analyst Esther Rajavelu set a Buy rating and raised her price target by 14%, to $97, saying, “We raise our PT as we now better appreciate the incremental Optune GBM revenue potential if used in conjunction with radiation therapy (vs post radiation). While a registrational trial and regulatory approval will be required prior to use, we view this incremental patient pool as low hanging opportunity beginning in 2023…” Her target indicates confidence in a 42% upside to the stock.With 3 Buy ratings given in the last three months, NVCR has a Strong Buy from the analyst consensus. The stock sells for $68.30, and the average price target of $97 implies room for a 43% upside. (See NovoCure stock analysis on TipRanks)
- Zacks
Will NovoCure (NVCR) Report Negative Earnings Next Week? What You Should Know
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
Style Box ETF report for FNY
- Business Wire
Results from STELLAR Trial of Tumor Treating Fields with Chemotherapy in Malignant Pleural Mesothelioma Published in The Lancet Oncology
Novocure (NVCR) today announced that results from the STELLAR trial were published in The Lancet Oncology. The STELLAR trial was a prospective, single-arm trial including 80 patients that studied the use of Tumor Treating Fields, delivered via the NovoTTF-100L System, in combination with pemetrexed plus cisplatin/carboplatin as a first-line treatment for patients with unresectable, locally advanced or metastatic malignant pleural mesothelioma (MPM). Data showed a median overall survival of 18.2 months (95 percent CI, 12.1 months-25.8 months) for patients treated with NovoTTF-100L and pemetrexed plus cisplatin or carboplatin.
